TDOCHealthcare · Health Information ServicesThe 23 Wall Street analysts covering Teladoc Health, Inc. hold a median 12-month price target of $8.75 — -9.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 3 Nov 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Teladoc Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (96): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (45): The share price moves around a lot.
Size (38): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on TDOC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −9.7% from it.
Of the 20 most recent actions, 7 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Nov 2026 | Barclays | Maintains | Equal-Weight | $7.00 → $9.00 |
| 2 Nov 2026 | Oppenheimer | Maintains | Outperform | $7.00 → $10 |
| 2 Nov 2026 | UBS | Maintains | Neutral | $6.50 → $9.00 |
| 30 Oct 2026 | JP Morgan | Maintains | Neutral | $8.00 → $10 |
| 29 Oct 2026 | Needham | Reiterates | Hold | — |
| 29 Oct 2026 | Stifel | Maintains | Hold | $5.50 → $6.50 |
| 3 Aug 2026 | Citigroup | Maintains | Neutral | — |
| 3 Aug 2026 | Citigroup | Maintains | Neutral | $11 → $7.50 |
| 30 July 2026 | Canaccord Genuity | Maintains | Buy | $11 → $10 |
| 30 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 30 July 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 30 July 2026 | Evercore ISI Group | Maintains | In-Line | $10 → $7.50 |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | $10 → $11 |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 7 July 2026 | B of A Securities | Maintains | Buy | $9.00 → $11 |
| 7 July 2026 | B of A Securities | Maintains | Buy | — |
| 5 May 2026 | Citigroup | Maintains | Neutral | — |
| 8 Apr 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 26 Mar 2026 | Barclays | Maintains | Equal-Weight | — |
| 13 Mar 2026 | JP Morgan | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
TDOC appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Teladoc Health, Inc. returned +21.4% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 77% of US stocks
Cheaper than 64% of US stocks
Cheaper than 14% of US stocks
Higher than 22% of US stocks
Higher than 32% of US stocks
Higher than 82% of US stocks
Higher than 28% of US stocks
Higher than 23% of US stocks
Higher than 35% of US stocks
Higher than 35% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Teladoc Health, Inc. has a market value of $1.8B and an enterprise value of $1.8B.
Revenue in the twelve months to 30 June 2026: $2.5B. The latest quarter shrank 3.4% year on year.
Net income over the same four quarters: −$177.4M, a −7.1% net margin.
Diluted earnings per share, trailing twelve months: $−0.99.
Free cash flow in the twelve months to 30 June 2026: $118.1M, after $130.4M of capital spending.
Trailing P/E: −8.5×; forward P/E: −15.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Teladoc Health, Inc. employs 4,648 people — $536K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Teladoc Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Teladoc Health announced that it issued inducement awards to three new employees under NYSE Rule 303A.08.
Why it matters — The announcement provides TDOC watchers with information about equity awards issued in connection with the hiring of three employees.
Teladoc Health shares rose 26% after the company beat estimates for sales and earnings, despite shrinking revenue. Early signs that BetterHelp may shift toward insurance-covered care were cited as a reason for the increase.
Why it matters — TDOC watchers may view the earnings beats and potential expansion of insurance-covered BetterHelp care as notable developments.
Teladoc shares traded higher Thursday after the company reported third-quarter results that exceeded expectations and raised its 2026 GAAP earnings-per-share guidance.
Why it matters — The results and higher guidance are updates for investors tracking Teladoc’s financial performance and outlook.
Seeking Alpha published a transcript of Teladoc Health, Inc.’s Q3 2026 earnings call. The excerpt provides no details from the call.
Why it matters — TDOC watchers can consult the transcript for management’s comments, but the provided excerpt does not describe the company’s results or outlook.
Teladoc Health reported third-quarter 2026 revenue near the upper end of its guidance range and adjusted EBITDA above expectations. Growth in Integrated Care and BetterHelp insurance revenue partly offset continued pressure in BetterHelp’s cash-pay business.
Why it matters — TDOC watchers may note the stronger reported revenue and adjusted EBITDA alongside ongoing weakness in BetterHelp cash-pay.
The 23 Wall Street analysts covering Teladoc Health, Inc. have a median 12-month price target of $8.75, with estimates ranging from $6 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 23 analysts covering Teladoc Health, Inc., 6 rate it a Buy, 16 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Teladoc Health, Inc. 86 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Teladoc Health, Inc. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (96 of 100).
No one can know that. What the data says: the median 12-month target from 23 analysts implies -9.7% from the last close, and Ticker Nerd's factor model ranks Teladoc Health, Inc. 86 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Teladoc Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TDOC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $12 over the next 12 months.
Teladoc Health, Inc. returned +21.4% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Teladoc Health Inc. is a virtual healthcare company that provides technology-enabled medical services for patients, employers, health plans, hospitals, and health systems.
The most recent item we track (GlobeNewsWire, 3 Nov 2026): "Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08". Teladoc Health announced that it issued inducement awards to three new employees under NYSE Rule 303A.08.
Teladoc Health Inc. is a virtual healthcare company that provides technology-enabled medical services for patients, employers, health plans, hospitals, and health systems. Its platform supports remote access to general medical care, mental health services, chronic condition management, specialty consultations, and expert medical opinions through phone, video, mobile, and web-based channels. The company operates through two main business segments: Integrated Care, which delivers enterprise virtual care solutions, and BetterHelp, a direct-to-consumer online mental health platform. Teladoc Health Inc. plays a significant role in the digital health market by connecting clinicians and care seekers through scalable, on-demand care delivery across a broad range of healthcare needs.
CEO Mr. Charles Divita III, CPA · 4,648 employees · United States · https://www.teladochealth.com
